Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma
Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Brunswick Exploration Announces Brokered Private Placement for Gross Proceeds of up to C$2.5 Million, with a Lead Order from a Strategic Investor
RETRANSMISSION: Group Eleven to be Featured on Radius Research for a Live Company Pitch, Deep Dive and Q&A Webinar
